Phase 3 EXCALIBER-RRMM Trial Results: Zenbexus (Iberdomide) in Combination with Daratumumab and Dexamethasone Showed Longer Progression-Free Survival vs Standard of Care in Relapsed/Refractory Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/phase-3-excaliber-rrmm-trial-results)